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Abstract 
 
Surgery is associated with release of local and systemic mediators which influence 
vascular and tissue homeostasis. The post-surgical release of acute phase reactants, 
particularly IL-6 and CRP, is reduced in minimally invasive surgery, compared 
with conventional surgery. Additionally, there is emerging evidence that leukocytes 
and Reactive Oxygen Species (ROS) are affected differentially by minimally 
invasive surgery.  
 
ROS and mediators of oxidative stress influence vascular endothelium, organ 
perfusion and angiogenesis, and may be critical determinants of survival and 
outcome. ROS also influence cell proliferation and cell death and have been 
implicated in neoplastic signalling. Advances in ROS detection and oxidative stress 
signalling have shown cellular changes affected by minimally invasive surgery. It 
has been observed that the invasiveness of surgery is proportional to changes in 
phagocyte and lymphocyte ROS. A potential role for ROS signalling in the immune 
system is suggested by evidence of closer ROS/leukocyte correlation in patients 
undergoing minimally invasive surgery. At lower ROS levels, phagocyte and 
lymphocyte ROS following minimally invasive surgery implicate a homeostatic 
response with closer leukocyte/ROS correlations, whereas higher ROS in open 
surgery and greater leukocyte depletion indicates more cytotoxic signalling.  
 
Interactions between humoral and cellular elements suggest that an integrated 
systems approach, using individual patient responses, should be used to analyse the 
response to surgical trauma and oxidative stress. These studies are being used to 
investigate ROS as biomarkers of the effects of surgery on vascular and pulmonary 
reactivity. ROS signalling may provide insights into post surgical trauma and its 
underlying pathology. 
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Introduction 
 
There is increasing evidence for the advantages of minimally invasive surgery in a variety 
of pathologies [1, 2]. However, there is surprisingly little quantitative analysis of 
molecular and cellular processes differentially affected by minimally invasive surgery. 
This is partly because multi-factorial processes are involved. These include less blood 
loss and  transfusion, lower anaesthetic use, and reduced tissue trauma in minimally 
invasive surgery [3]. In this review, these diverse factors and networks will be discussed 
in terms of cellular and humoral mediators and Reactive Oxygen Species (ROS) 
signalling as a regulatory process in surgical stress.  
 
The networks affected by surgical processes include immune, inflammatory, stress 
signalling and vascular systems. Circulating biomarkers of these networks provide 
evidence of mediators and cellular responses differentially affected by minimally 
invasive surgery [4-7]. There have been advances in the characterisation of mediators 
released during surgery, including eicosanoids, anaphylactic mediators [8-14] and factors 
affecting pulmonary oncogenesis [15-18]. An early response to surgery is the release, 
within minutes to hours, of humoral mediators including acute phase proteins, cytokines, 
ROS [19-21], lipid mediators, adrenocorticoids and catecholamines. These mediators 
influence vascular permeability, tissue perfusion and metabolic breakdown processes, 
known as catabolism [22-24].  Although some of these responses result in homeostasis, 
the catabolic state may be serious or fatal, especially in the immediate post surgical 
period.  Over a longer period, hours to days after surgery, changes in humoral immune 
mediators are associated with altered leukocyte distribution and activity [7]. There is 
evidence of ROS involvement in immune responses, where lymphocyte ROS are 
associated with proliferative signalling at low concentrations and inhibition of 
lymphocyte activity at higher concentrations. Humoral immune mediators (including 
ROS) influence the immune system via host specific antibody production [17] and act on 
effector cells such as mononuclear and polymorphonuclear phagocytes and natural killer 
(NK) cells [4, 25].  The cellular arm of the immune system therefore responds to 
circulating and local mediators, and produces ROS and other mediators in response to 
surgical trauma. It will be proposed that a regulatory response to surgical trauma lies in 
the reticulo-endothelial system, where ROS associated endothelial damage may result in 
multi organ failure, or influence tumour development, angiogenesis and metastasis [26-
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28]. The effects of minimally invasive surgery on various endpoints must therefore be 
considered. In addition to survival, effects on immunity, oncogenic processes and 
vascular and tissue metabolism must be determined.  
 
This review will analyse humoral and cellular mediators differentially affected by 
minimally invasive surgery compared with open surgery (Table 1), with specific focus on 
early triggering mediators detected during the surgery of pulmonary neoplasms. The 
impact of surgical trauma on circulating immune cells will be discussed in relation to 
ROS effects on innate and acquired immunity and the vasculature. Recent evidence of 
interactions between immunological and humoral mediators, indicating connectivity 
between humoral and cellular mediators of surgical stress will be presented. 
Accumulating evidence, suggesting that minimally invasive techniques reduce specific 
stress responses, leading to different cellular fates and reduced cytotoxicity, will be 
reviewed. Correlations between ROS activity and leukocyte distribution also suggest that 
further attention should be paid to metabolic and oxidative activities at cellular and 
systemic levels.   
 
Table 1. Circulating Cellular and Humoral Mediators of Surgical Stress affected 
differentially by Minimally Invasive Surgery. The response to open surgery and 
minimally invasive surgery (brackets) is indicated by + (increase) or – (decrease). IgG, 
IgM, IgA (Immunoglobulins G, M, A); IGFBP-3 (insulin growth factor binding protein-
3); 
Mediator/ Biomarker 
Interleukin-6   
C-reactive protein 
Serum amyloid-A 
Phagocyte numbers, activity 
ROS 
Lymphocytes (T,B, CD4/8, NK) 
IgG, IgM and IgA 
Immunokine (IGFBP-3, MMP-9) 
Response  
+++ (++/-) 
+++ (++) 
+++ (++) 
++ (+) 
++ (+)  
-- (+) 
-- (--)  
-- (-), ++ (+) 
Peak change 
4-24h    
48h 
48h 
24h 
48h 
48h 
48h 
72h 
Ref 
[4, 19] 
[19, 2] 
[29] 
[6, 20] 
[12, 20] 
[4, 7, 29]  
[4, 17] 
[29] 
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Circulating Cellular and Humoral Mediators of Surgical Stress affected 
differentially by Minimally Invasive Surgery 
 
It is well established that a primary response to surgical stress is the acute phase response, 
in which acute phase proteins, including C-Reactive Protein (CRP), serum amyloid A, the 
acute phase cytokine, Interleukin-6 (IL-6) and complement are rapidly released (Table 1 
and Fig 1). This response is distinct from the elevation of acute phase reactants associated 
with infectious complications, and depends on tissue type, as well as the invasiveness of 
surgery.  Acute phase and cytokine changes associated with minimally invasive surgery 
are discussed further below. 
 
Other changes in small molecular weight metabolites and serum metabolites have also 
been detected in minimally invasive surgery, compared with conventional surgery, 
such as urea and haemoglobin. However, these metabolites are more closely linked to 
renal function and haemodilution, which are less affected by minimally invasive 
surgery. Local pH and perfusion (pO2, pCO2) may also be linked to blood loss [30]. 
Many other metabolites affected by minimally invasive surgery also tend to be 
localized in excised tissue and vasculature. Intermediary metabolites associated with 
the stress response include α-ketoglutarate/glutamate/glutathione, which influence 
ROS production and bioactivity, and succinate and oxaloacetate in the citric acid 
cycle and pyruvate/acetate in gluconeogenesis which are a target of ROS activity [31]. 
However, a wide range of metabolites including lipoprotein, glucose, lactate, 
pyruvate, citrate, formate, acetate and amino acids are also elevated in tumour tissue 
[32]. Therefore, it is essential to monitor presurgical levels of these metabolites and to 
determine changes in individual patients after surgery.  
 
Another group of metabolites associated with the invasiveness of surgery are linked to 
vascular endothelial function. Thus, in the brain, glutamate may report on endothelial 
cell function and the permeability of the blood brain barrier following surgery [33], 
and there is preliminary evidence that interstitial pyruvate and amino acids may link 
to consciousness in a rabbit model of subarachnoid haemorrhage [34]. Soluble 
adhesion molecules may also report on the extent of surgical invasiveness. Other 
circulating factors recognised to be differentially influenced by minimally invasive 
surgery include immunoglobulins and the related T and B cells, although these factors 
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are also affected by blood loss. Neurendocrine factors also affect the stress response 
in surgical patients [35] but have not been analysed in prospective randomised trials 
of minimally invasive surgery. These factors may also reflect anaesthesia levels, 
which are often lower in minimally invasive surgery. 
 
Acute Phase Response, Cytokines and ROS following Minimally Invasive Surgery 
 
During the acute phase response to surgical stress. acute phase proteins, the acute phase 
cytokine, Interleukin-6 (IL-6) and complement are rapidly released (Fig 1). This response 
depends on the invasiveness of surgery.  Following over twenty years of cytokine 
analysis, a specific sequence of cytokine changes have been linked to surgery, and there 
is recent evidence that these affect subsequent ROS and microvascular responses.  
 
The cytokine profile associated with surgical trauma (transiently high IL-6, low tumour 
necrosis factor- α; TNF- α) is affected differentially by minimally invasive techniques. A 
characteristic of minimally invasive surgery is attenuation of post surgical CRP and IL-6 
changes, compared with conventional surgery [3, 36]. These cytokine signals are closely 
linked to ROS, eicosanoid and lipoxygenase products, which have specific effects on 
pulmonary inflammation, oncogenesis and angiogenesis [8, 12, 37, 38]. Associated 
procedures and processes such as transfusion and haemorrhage also modulate the 
cytokine profile associated with trauma [5]. IL-6 and activated complement are released 
from tissue during surgery, and pulmonary mRNA expression of IL-6 and 
proinflammatory cytokines increase following surgery [21]. CRP and cytokines including 
IL-6 are also released during muscle injury [39]. The effects of acute phase reactants and 
cytokines associated with surgical stress on oxidative metabolism are complex, both 
facilitating ROS release in the early phase and down-regulating ROS damage in the later 
phase of the stress response. IL-6 is important in initiating inflammatory type reactions, 
while CRP binds damaged tissue, nuclear antigens and certain pathogens, assisting in 
their clearance. CRP acts in the innate immune system. Like IgG, CRP activates 
complement and binds Fc receptors, leading to an amplification of pro-inflammatory 
cytokine generation. Complement Factor H was recently shown to protect against 
oxidative stress by binding lipoxidation products [40]. CRP also recognizes altered self 
 7 
and foreign molecules, providing an early defense, and activating adaptive immunity 
[41].  
While the cytokine profile for different surgical targets varies, generally the minimally 
invasive route is associated with attenuation of stress-related cytokine signalling. Thus, in 
a study of minimally invasive and open surgery for rectal cancer, IL-2 decreased after 
surgery in both groups. However, pro-inflammatory IL-6 decreased 1 and 5 days after 
minimally invasive surgery, but increased after open surgery, while no change in 
TNF was detected [4]. Characteristic cytokine changes after pulmonary lobectomy 
included elevated IL-6, with substantially greater increases 48 hours after open surgery 
[19]. IL-6 regulates the release of factors affecting tissue oxidative metabolism and the 
tissue microenvironment, which have been reported to be differentially affected by 
minimally invasive surgery. Insulin growth factor binding protein (IGFBP-3), which is 
inhibited by IL-6, increased, and matrix metalloproteinase (MMP-9), which is stimulated 
by IL-6, decreased in minimally invasive, compared to open surgery [29]. Matrix 
metalloproteases and oxidative metabolism are associated with local ROS formation (see 
Mediators of Oxidative Stress, below) and these influence immune surveillance and 
tumour recurrence. Effects of minimally invasive surgery on immunoglobulins and 
leucocyte ROS have been observed [20] and will also be discussed. 
 
Fig 1. Interactions of ROS, Humoral and Cellular Mediators of Pulmonary Surgery. Mediators 
differentially affected by minimally invasive surgery are shown, together with products of lipid 
oxidation, prostaglandins (PGs) and lipoxygenase products (LO). Differential effects of moderate 
(green) and high (red) ROS levels on cells of the vasculature and lung parenchyma are shown. 
Humoral mediators and associated ROS signalling may link surgical stress and 
pathophysiological responses. Thus, high ROS concentrations can rapidly disrupt 
vascular endothelial and endothelial cell function and influence tumour associated 
angiogenesis. At lower ROS concentrations, however, homeostatic responses have been 
detected. It is proposed that lower ROS levels associated with minimal access surgery are 
involved in homeostatic change in immune and reticuloendothelial responses. At higher levels, 
ROS may exert cytotoxicity towards residual tumour cells. 
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Surgery and Oxidative Stress 
 
Recent advances in ROS analysis have improved our understanding of oxidative stress in 
patients undergoing surgery. Nanotechnology and microarrays to detect localized 
cytokine, immunokine and lipid mediators in cells and tissues have been linked to probes 
sensitive to ROS and redox activity [21]. These approaches require rigorous 
standardization of cellular and patient responses. However, they can be used to detect 
rapid signalling and metabolic changes in blood vessels and tissues in vivo. The concept 
of ROS as signalling elements requires different approaches to analysis, due to the 
distinct character of ROS, compared with other humoral signals such as cytokines and 
acute phase proteins. ROS are able to cross membranes and therefore their targets may be 
intracellular and transcellular (see Cellular Mediators of Oxidative Stress section below). 
However, ROS are also relatively short range, localized mediators, due to their rapid 
turnover and antioxidant activity (Table 2). 
 
Normal oxidative metabolism leads to limited ROS generation which is below the 
antioxidant capacity of the cell. Both ROS generation and antioxidant activity vary 
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between cell types, however, the balance between ROS production and consumption, and 
the localisation of these processes is crucial in determining homeostatic and cytotoxic 
responses (see Fig 1). In particular, high levels of superoxide anion (O2-) and its 
dismutation product, hydrogen peroxide, may lead to oxidative stress. Additionally, 
oxidative stress may arise through specialized enzymes of the reticuloendothelial system, 
such as NADPH oxidase, nitric oxide (NO) synthetase, cyclooxygenase, and lipoxidase, 
which produce hydrogen peroxide, superoxide, hydroperoxide, NO, peroxynitrite and 
lipid peroxides (Table 2). Oxidative stress is associated with local and systemic release of 
ROS, cytokines, lipid and stress mediators. Thus, the extent and characteristics of 
oxidative stress depends on micro-environmental factors and cellular ROS producing 
enzymes (which are highly active in phagocytes in the innate immune system). There is 
currently much research into cellular mediators of ROS action. These mediators are 
diverse, they depend on cellular redox activity and factors induced by surgical trauma 
[42], and vary between cells and tissues [43, 44]. This is particularly relevant to 
pulmonary surgery, where oxygen concentrations are high. Pulmonary ROS are closely 
regulated, and specific pathways control pulmonary endothelium, whose vasoactivity is 
selectively sensitive to lipoxygenase mediators and oxygen tension [15, 16, 45]. Cells 
derived from non small lung cancer are also highly sensitive to ROS [8, 46].  
 
ROS formed during oxidative stress are transiently produced, but can have profound 
effects on cell and tissue metabolism and organ fate [9, 16, 24, 34]. ROS change cellular 
responses through diverse mechanisms. At low levels, ROS may act as signalling 
molecules, whereas higher localized ROS concentrations may damage organelles, 
particularly mitochondria. Oxidative damage and associated mitochondrial dysfunction 
may elicit energy depletion, accumulation of cytotoxic mediators and cell death [47, 48]. 
Thus, while low ROS levels often stimulate physiological growth and activity, higher 
levels may lead to oxidative stress and pathological responses in vascular and pulmonary 
systems [23]. The interface between stress adaptation and cell death is important in 
disease pathogenesis. Autophagy, one of the main catabolic pathways, links these 
processes and has also been postulated to play a role in hypoxia and tumour development 
[49, 50]. 
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Table 2 ROS formation in Human Cells and Tissues. 
Mediators of Oxidative Stress  
Superoxide [16, 43]   
Hydrogen peroxide [51]   
Hydroperoxide    
Peroxynitrite      
Lipid peroxides  [8, 45]   
      
      
Metabolic Factors 
Oxygen 
Glucose 
ATP 
Redox active iron(haemolysis) [52, 53] 
Polyunsaturated fatty acids [44, 47, 48] 
Phagocytes [51] 
Reperfusion [27] 
ROS production 
Mitochondrial respiratory chain[37, 41] 
NADPH oxidase (phagocytes, endothelial cells, erythrocytes) [24, 27] 
Nitric oxide synthetase (eNOS, nNOS, iNOS) [27] 
Xanthine oxidase 
Monoamine oxidase 
Lipoperoxidases [43-45] 
Antioxidants     
Reduced glutathione (GSH)   
Vitamin C, E     
      
ROS consumption 
Superoxide dismutase [16] 
Catalase [51] 
GSH peroxidises/reductases [16] 
 
 
Phagocyte ROS in Minimally Invasive Surgery 
 
There is increasing evidence that phagocyte ROS are up-regulated by surgery, and that 
minimally invasive techniques modulate this release. Recent evidence suggests that ROS 
production following minimally invasive surgery falls close to the transition point 
between homeostatic and cytotoxic responses. An effect of minimally invasive thoracic 
surgery (VATS) has been reported on phagocyte ROS [6, 20]. Postsurgical ROS 
increased in monocytes and neutrophils, using an assay which indicated ROS/ mortality 
associations in patients with sepsis [54]. Open surgery elicited twice as much neutrophil 
ROS as minimally invasive surgery two days after pulmonary surgery [20]. In order to 
analyse the correlation between ROS and leukocyte mobilisation, blood leukocyte counts 
and their oxidative activity were compared in individual patients. NK cells and phagocyte 
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ROS showed different changes after minimally invasive and open surgery (Fig 3A). The 
higher ROS in open surgery patients showed negative correlations, when ROS and 
lymphocyte numbers were compared. This may reflect leukocyte cytotoxicity and tissue 
and reticulo-endothelial uptake, leading to loss of circulating lymphocytes. In contrast, 
positive correlations in minimally invasive surgery patients indicated tighter coupling 
between leukocyte oxidation and lymphocyte numbers.  
 
Thus, moderate ROS production in minimal access surgery may exert a homeostatic 
function, where antioxidant defences are able to limit ROS associated cytotoxicity (Fig 
1). A homeostatic link between immune factors and phagocyte ROS has been reported in 
immunodeficient patients, where IgG inhibited monocyte ROS and stimulated CD8 
lymphocyte count [55]. However, there is evidence that activated phagocytes may also 
inhibit lymphocyte reactivity via ROS: At higher ROS concentrations, activated 
human blood monocytes and neutrophils suppressed lymphocyte mitogenesis, suggesting 
a cytolethal suppressive mechanism. Suppression was prevented by catalase, implicating 
H2O2 as a mediator [51]. 
 
Lymphocyte ROS in Minimally Invasive Surgery 
 
Minimally invasive surgery results in moderate immunosupression [3, 4, 7] and 
disturbances of immune function may predispose to increased tumour growth/recurrence.  
Decreases in circulating immunoglobulin and lymphocytes provide evidence of post 
surgical immunosuppression, which is reduced in minimally invasive surgery, Leaver et 
al 2014, Cellular Metabolomics, 2 (3) in press. T and B lymphocytes play key roles in 
post surgical infection. Changes in T and B leukocyte and NK cell numbers, and 
decreased T helper/suppressor cell ratios (CD4/8) were detected 7 days post- surgery and 
were lower in patients undergoing minimal access surgery, indicating a cellular immune 
system which was less affected by minimal access surgery [20, 36]. In lung cancer, NK 
cells play a cytotoxic role [56], and acquired immune responses are involved in tumour 
recognition [57] and killing. In rectal cancer, NK cells decreased postoperatively in 
laparoscopic and open surgery. [4]. Postoperative IgG and IgA decreases after open and 
closed heart surgery were more significant after open surgery, and reflected decreased 
antibacterial immunity and higher infection rates in open surgery [17]. Decreased serum 
IgA, IgG and IgM also occur following liver transplantation: rapid decreases on the first 
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few days after surgery were followed by moderate increases [58]. In a prospective study 
of pulmonary lobectomy, IgG, IgA, and IgM decreases showed close correlations (Fig 2), 
suggesting similar depletion processes. Similar post-surgical changes were detected in 
laparoscopic cholecytstectomy [59].  
 
Cellular changes differentially affected by minimally invasive surgery include leukocyte 
cell numbers [7] and their oxidative activity [20]. Until recently, lymphocyte ROS 
production received less attention than the antimicrobial role of ROS in innate immunity. 
However, there is evidence for ROS signalling in adaptive immunity. T lymphocyte 
activation, through specific antigen receptor, T cell receptor (TCR), is vital in regulating 
the immune response. Redox dependent T cell activation was detected during T cell 
signalling and gene expression, when TCR engagement induced rapid ROS production 
[60, 61].  
 
There is also evidence of lymphocyte ROS signalling in inflammatory disease, as T 
lymphocyte ROS correlate with T cell mitogenic responsiveness [62]. Increased ROS 
signalling was associated with intravenous iron preparations in haemodialysis patients, 
which reduced lymphocyte survival [52]. Lymphocyte ROS increased 15% following 
open surgery, but only 4% two days after minimal access surgery [20]. Lymphocyte ROS 
resembled phagocyte ROS, showing closer correlation in minimal access, compared with 
open surgery (Fig 3B). Thus, 48 hours after surgery in minimally invasive surgery 
patients, lymphocyte ROS correlated positively with lymphocyte numbers. However, in 
open surgery, there was negative correlation between higher ROS and lymphocyte 
numbers. These differences were transient, and were greater at two days after surgery.  
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Fig 2. Cellular Immune Responses 
and ROS in Leukocytes of patients 
undergoing Open (o, blue bars) and 
Minimally Invasive (v, pink bars) 
Thoracotomy. Peripheral blood 
leukocytes and ROS in 41 patients 
undergoing pulmonary lobectomy 
were compared, leukocyte oxidative 
activity (ox) was analysed, using 
healthy blood donors as control. A) 
Correlation of post surgical change in 
absolute lymphocyte count (Ba, 
CD8a, CD4a) and absolute Natural 
Killer count (NKa), monocyte (mono 
ox) and neutrophil (neutr ox) ROS 
were compared on 2 and 7 days post 
op for open surgery (o2, o7) and 
VATS (v2, v7) patients. B) 
Correlation of lymphocyte and 
lymphocyte ROS (lox) in same 
patients.  
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Cellular Mediators of Oxidative Stress  
 
The importance of oxidative signalling in response to surgery is shown in the early genes 
up-regulated in leukocytes. Of the 17 up-regulated genes detected four hours after cardiac 
surgery, 53% were related to oxidative and metabolic stress signalling, while only 30% 
were linked to cytokine and chemokine responses [21]. In this section, some of the 
primary cellular targets of ROS will be discussed in relation to surgical stress and the 
networks affected by surgery.  
 
A primary response factor sensitive to ROS is transcription factor NF-κB, which plays a 
major role in coordinating innate and adaptative immunity, cell proliferation, apoptosis 
and development via IκBα and IκB kinase (IKK). Molecular mechanisms leading to IKK 
activation are cell specific, and various ROS including HOCl, superoxide 
and reactive nitrogen species affect NF-κB. ROS are involved in NF-κB activation by 
pro-inflammatory cytokines (TNF-α, IL-1β) [63-65]. Another key transcription factor in 
ROS signalling and tumour progression is hypoxia-inducible factor (HIF) [18, 66, 67]. 
Recent research suggests that HIF induction has serious consequences in diseases with a 
chronic inflammatory component, such as lung cancer [15, 68]. It has also been shown 
that chronic inflammation is self-perpetuating, distorting the microenvironment and 
eliciting aberrant transcription factors. Both NF-κB and HIF interact with lipid mediators 
and cytokine networks in response to ROS associated signals, and vascular and 
transformed cells are specific targets of this signalling  [69].  
  
ROS also influence endothelial cell function via Vascular Cell Adhesion Molecule-1 
(VCAM-1), which, in concert with microenvironmental factors, regulates leukocyte 
migration from blood into tissues. Endothelial VCAM-1 expression is induced during 
inflammatory bowel disease, atherosclerosis, allograft rejection, infection and asthma. 
VCAM-1 signals are mediated by ROS and matrix metalloproteinases (signals required 
for endothelial cell shape change and leukocyte migration). Additionally, endothelial cell 
VCAM-1-activated signals are regulated by inflammatory cytokines [70 ]. A link 
between blood phagocyte activation, ROS and oxidative stress following reperfusion was 
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suggested by upregulation of leukocyte adhesion and migration receptors following 
cardiac surgery [21] . Additionally, oxidative stress is increased following reventillation 
[71]. Further cellular influences, related to immunological mechanisms and ROS were 
detected in erythrocyte transfusions. Aged erythrocytes are associated with complications 
following cardiac surgery [72] and oxidative stress has been proposed to initiate RBC 
ageing processes [73]. A feedback link between ROS and the intrinsic immune system 
lies in signal inhibitory receptor on leukocytes-1 (SIRL-1). SIRL-1 ligation dampens Fc 
receptor-induced ROS production in primary human phagocytes [74]. 
 
High ROS concentrations can cause cell death in lung cancer cells, and there is increasing 
evidence that this is a primary pathway of tumour regression [46, 47]. Micro-
environmental elements controlling tumour transformation, development and associated 
vascularisation are currently the focus of therapeutic development. Apoptosis of human 
lung epithelial cancer H460 cells, inhibited by ROS scavengers or antioxidant enzymes 
(glutathione peroxidase and superoxide dismutase), indicate a role for ROS, especially 
hydroperoxide and superoxide anion, via the mitochondrial death pathway, involving 
caspase-9 and down-regulation of mitochondrial Bcl-2 through peroxide-dependent 
proteasomal degradation [16]. However, ROS are also involved in tumour progression 
[75] and resistance to anti-proliferative signals e.g. increased human cardiac fibroblast 
resistance to oxidative stress associated with elevated FOXO3a, involving receptor-
interacting kinase 1 and TNFα [43]. ROS signalling elements are therefore being used to 
characterize tumour regression pathways and signals. The effects of the lower ROS levels 
associated with minimally invasive surgery, and whether localized ROS amplification at 
the site of surgery would be desirable requires further investigation. 
 
Direct and Indirect Approaches to ROS Analysis: Metabolomics and Cell Biology 
 
As described in Table 2, a range of metabolites and systems are involved in ROS 
production and bioactivity, and an informed metabolomic approach should ideally 
analyse multiple overlapping products and targets. This is particularly relevant in the 
clinical setting, where underlying vascular, metabolic, degenerative or oncogenic disease 
may affect ROS production and responses. 
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ROS may be measured either directly, using spin trap methods or fluorescent substrates, 
or indirectly, in terms of ROS producing systems, or systems and metabolites affected by 
ROS. Some of the early cellular and mediator responses, such as stress kinases, stress 
factors such as HIF, matrix metalloproteases and apoptosis signals have already been 
described. A complimentary approach is to determine metabolic flux in the enzyme 
systems and organelles that produce and respond to ROS, such as NADPH oxidase, and 
mitochondria (membrane potential, permeability transition pore, cytochrome c release). 
Improved metabolic indicator analysis to determine respiratory control and redox status 
are widely used in toxicology and oncology to determine bioenergetic status, including 
ATP/ADP ratios, lipid oxidation products and metabolites increased by ROS. 
Intermediary metabolites which influence ROS production and bioactivity include α-
ketoglutarate/glutamate/glutathione, and targets of ROS include succinate and 
oxaloacetate in the citric acid cycle and pyruvate/acetate in gluconeogenesis [31]. 
Additionally, an important indicator of ROS bioactivity is antioxidant status, both 
intracellular and extracellular. Thus thiol group redox status and glutathione levels are 
often monitored, particularly in pharmaceutical and nutraceutical contexts, where many 
novel redox active compounds, often derived from traditional medicines, such as the 
flavinoids are showing promise. In summary, in the rapidly growing field of ROS 
characterization, some of the strongest evidence comes from multidisciplinary 
approaches, but metabolomics is at the forefront of advances in analysis of bioactivity 
and potential therapeutic advances. 
 
Conclusions 
 
Surgery elicits the release of an interconnected network of mediators, acting in patients 
whose vascular system may be compromised by underlying disease. In minimally 
invasive surgery, reduced acute phase responses have been observed, compared with 
conventional surgery. Post-surgical anergy is also a recognised effect in hours and days 
immediately following surgery, and differential effects of minimally invasive surgery 
have also been detected on circulating lymphocytes and secreted immunoglobulins (Table 
1, Fig 2).  
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Fig 3. Dendrograph indicating links between ROS and Humoral and Cellular Mediators following 
Surgery. This figure shows the correlation (red: negative, green: positive) between changes in 
factors reported to differ in A) Open surgery, and B) Minimally invasive (VATS) patients after 
surgery. Indicators of haemodilution: urea and blood loss (BL) 24h after surgery showed negative 
correlation with Haemoglobin (Hb), this correlation was similar in VATS patients. Also, 
correlations between IgG and IgA were similar in VATS and open surgery, 2 days after surgery. 
In contrast, there was a negative correlation between lymphocyte number/lymphocyte ROS 2 
days after open surgery, but there was a positive correlation in VATS patients, supporting the 
hypothesis that higher ROS levels in open surgery were cytotoxic. Differences between 
VATS/open surgery were also detected in phagocyte monocyte (mROS) and neutrophil (nROS), 
compared with Complement (C3 and C4) 7 days after surgery. Greater negative correlations 
between complement C3 and C4 and phagocyte ROS were detected in the open surgery group.  
 
 
 
A factor that links humoral and cellular responses to surgical stress is oxidative 
metabolism in leukocytes and the vasculature. The extent of phagocyte and lymphocyte 
ROS production was also proportional to the degree of invasiveness of surgery. ROS 
research is a rapidly developing field, and more evidence is currently available from 
circulating ROS associated signals following surgery than ROS effects on target tissues. 
However, it is well established that leukocyte ROS have effects on vascular endothelium, 
organ perfusion and angiogenesis (Fig 1). Phagocyte and lymphocyte ROS also influence 
the immune system, with low concentrations stimulating mitogenesis and lymphocyte 
proliferation, and higher concentrations being inhibitory and cytotoxic. ROS associated 
interactions between systemic and cellular elements suggest that an integrated systems 
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approach, involving individual patient responses, is important in analysing the effects of 
surgery on immunity and oncogenesis.  
 
With their rapid release, ability to cross membranes, and sensitivity to micro-
environmental and cell specific signals, ROS play a local signalling role, mediating cell 
and tissue homeostasis and damage responses. Future investigations of the impact of 
minimally invasive surgery should include rapidly turning over mediators of oxidative 
stress, their immunological activities (Figs 2 and 3) and vasoactivity in the immediate 
post surgical period. Additionally, pulmonary effects of these mediators must be 
considered. Finally, chronic influences are important in this patient group, where periods 
of hypoxia and vascular damage may lead to tissue damage or tumour development. It is 
important to analyse localized vascular and pulmonary changes, and new imaging 
techniques [76], together with microanalysis and probes of ROS and oxidative stress [23, 
77] will provide insight into these processes. 
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